These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15136772)

  • 41. Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
    Sampaio C; Ferreira JJ
    Nat Rev Neurol; 2010 Nov; 6(11):590-1. PubMed ID: 21048799
    [No Abstract]   [Full Text] [Related]  

  • 42. Drugs for treating Parkinson disease.
    Belavic J
    Nursing; 2012 Jul; 42(7):69. PubMed ID: 22739529
    [No Abstract]   [Full Text] [Related]  

  • 43. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 45. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 46. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 47. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

  • 50. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
    Polo O; Ylä-Sahra R; Hirvonen K; Karvinen J; Vahteristo M; Ellmén J
    Clin Neuropharmacol; 2007; 30(6):335-44. PubMed ID: 18090458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
    Bokor M; Szentesi A
    Ideggyogy Sz; 2010 Jul; 63(7-8):247-51. PubMed ID: 20812452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    Simonson W; Hauser RA; Schapira AH
    Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?
    Basile S; Pinelli S; Garibaldi S; Altamura C; Calcagno M; Salerno MG
    J Obstet Gynaecol; 2017 Apr; 37(3):381-382. PubMed ID: 28013564
    [No Abstract]   [Full Text] [Related]  

  • 55. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

  • 56. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study.
    Zangaglia R; Stocchi F; Sciarretta M; Antonini A; Mancini F; Guidi M; Martignoni E; Pacchetti C
    Clin Neuropharmacol; 2010; 33(2):61-6. PubMed ID: 19935405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sinemet - 25/100.
    Med Lett Drugs Ther; 1980 Jun; 22(12):51. PubMed ID: 7374623
    [No Abstract]   [Full Text] [Related]  

  • 60. Finasteride attenuates pathological gambling in patients with Parkinson disease.
    Bortolato M; Cannas A; Solla P; Bini V; Puligheddu M; Marrosu F
    J Clin Psychopharmacol; 2012 Jun; 32(3):424-5. PubMed ID: 22534502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.